Researchers at Cima and Clinica Universidad de Navarra have identified new molecular mechanisms underlying multiple myeloma. This type of hematologic cancer, which affects the bone marrow, is ...

Johnson & Johnson JNJ announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use ...

A new clinical trial shows that TALVEY, an immunotherapy drug, works even better when given to myeloma patients earlier.

The International Myeloma Foundation (IMF) is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI) cure trial, Aggressive Smoldering Curative ...

A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in ...

Johnson & Johnson (NYSE:JNJ) reported Phase 3 results for TALVEY plus DARZALEX FASPRO in relapsed or refractory multiple ...

FDA Approves First Bispecific Antibody, Teclistamab, for R/R Multiple Myeloma Although exercise during cancer treatment is encouraged, multiple myeloma can present special challenges, since there is ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

A recent study found that the majority of interventional phase 3 trials lacked a clear definition of high-risk multiple myeloma, and many patients were missing important data for risk stratification.